Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Viral overexpression of human alpha-synuclein in mouse substantia nigra dopamine neurons results in hyperdopaminergia but no neurodegeneration.

Autor: Garcia Moreno SI; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Limani F; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Ludwig I; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Gilbert C; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria., Pifl C; Center for Brain Research, Medical University of Vienna, Vienna, Vienna, Austria., Hnasko TS; Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; Department of Veterans Affairs, San Diego Veterans Affairs Healthcare System, San Diego, CA, USA; Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA., Steinkellner T; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. Electronic address: thomas.steinkellner@meduniwien.ac.at.

Publikováno v: Experimental neurology [Exp Neurol] 2024 Dec; Vol. 382, pp. 114959. Date of Electronic Publication: 2024 Sep 15.

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

Autor: Sam J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Hofer T; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Kuettel C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Claus C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Thom J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Herter S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Georges G; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Korfi K; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Lechmann M; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Eigenmann MJ; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Marbach D; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Jamois C; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Lechner K; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Krishnan SM; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Gaillard B; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Marinho J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Kronenberg S; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Kunz L; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Wilson S; Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Welwyn Garden City, United Kingdom., Briner S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Gebhardt S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Varol A; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Appelt B; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Nicolini V; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Speziale D; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bez M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bommer E; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Eckmann J; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Hage C; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Limani F; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Jenni S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Schoenle A; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Le Clech M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Vallier JP; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Colombetti S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bacac M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Gasser S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Klein C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Umaña P; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.

Publikováno v: Blood [Blood] 2024 May 23; Vol. 143 (21), pp. 2152-2165.

Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study.

Autor: Phillips MT; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St., P.O. Box 208034, New Haven, CT, 06520-8034, USA., Antillon M; Swiss Tropical and Public Health Institute, Basel, Switzerland., Bilcke J; Center for Health Economics Research and Modeling Infectious Diseases, University of Antwerp, Antwerp, Belgium., Bar-Zeev N; International Vaccine Access Center, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.; Malawi Liverpool Wellcome Programme, Blantyre, Malawi., Limani F; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Kamuzu University of Health Sciences, Blantyre, Malawi., Debellut F; Center for Vaccine Innovation and Access, PATH, Geneva, Switzerland., Pecenka C; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Neuzil KM; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA., Gordon MA; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Kamuzu University of Health Sciences, Blantyre, Malawi.; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Thindwa D; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK., Paltiel AD; Department of Health Policy, Yale School of Public Health, New Haven, CT, USA., Yaesoubi R; Department of Health Policy, Yale School of Public Health, New Haven, CT, USA., Pitzer VE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St., P.O. Box 208034, New Haven, CT, 06520-8034, USA. virginia.pitzer@yale.edu.

Publikováno v: BMC infectious diseases [BMC Infect Dis] 2023 Mar 08; Vol. 23 (1), pp. 143. Date of Electronic Publication: 2023 Mar 08.

Estimating the economic burden of typhoid in children and adults in Blantyre, Malawi: A costing cohort study.

Autor: Limani F; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi., Smith C; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi., Wachepa R; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi., Chafuwa H; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi., Meiring J; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi., Noah P; Department of Surgery, Kamuzu University of Health Sciences, Queen Elizabeth Central Hospital, Blantyre, Malawi., Patel P; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi., Patel PD; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi., Debellut F; PATH, Seattle WA, United States of America., Pecenka C; PATH, Seattle WA, United States of America., Gordon MA; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom., Bar-Zeev N; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.; Department of International Health, International Vaccine Access Center, Bloomberg School of Public Health, Johns Hopkins University, Baltimore MD, United States of America.

Publikováno v: PloS one [PLoS One] 2022 Nov 23; Vol. 17 (11), pp. e0277419. Date of Electronic Publication: 2022 Nov 23 (Print Publication: 2022).